Cardiac Pharmacology: Difference between revisions

Jump to navigation Jump to search
no edit summary
No edit summary
Line 124: Line 124:
|-
|-
!Drug
!Drug
!Drugs that <big></big> drug action
!Drugs that ↑ drug action
!Drugs that <big></big> drug action
!Drugs that ↓ drug action
|-
|-
!Digoxin
!Digoxin
Line 328: Line 328:
!Side Effects (Prevalence %)
!Side Effects (Prevalence %)
|-
|-
|colspan="5"|
|colspan="5" bgcolor="#E6E6FA"|'''Anti-hypertensives'''
|-
!colspan="5"|Anti-hypertensives
|-
|-
|rowspan="2"|Diuretics
|rowspan="2"|Diuretics
Line 407: Line 405:
|Nifedipine: 5-20mg 3 times daily
|Nifedipine: 5-20mg 3 times daily
|-
|-
!colspan="5"|Anti-Arrhythmics
|colspan="5" bgcolor="#E6E6FA"|'''Anti-Arrhythmics'''
|-
|-
|Class I (sodium channel blockers)
|Class I (sodium channel blockers)
Line 442: Line 440:
|62.5-125 µg daily
|62.5-125 µg daily
|-
|-
!colspan="5"|Anti-platelet Drugs
|colspan="5" bgcolor="#E6E6FA"|'''Anti-platelet Drugs'''
|-
|-
|rowspan="7"|
|rowspan="7"|
Line 474: Line 472:
|Dyspnoea (13.8%), haemorrhage, bruising; nausea (4.3%), vomiting, diarrhoea (3.7%), hypertension (3.8%), hypotension (3.2%), back pain (3.6%), abdominal pain, dyspepsia, gastritis, dizziness (4.5%), chest pain (3.7%), headache (6.5%), cough (4.9%), rash, pruritus, fatigue (3.2%),  constipation, arrhythmias including atrial fibrillation (4.2%), paraesthesia, confusion, hyperuricaemia, raised serum creatinine (7.4%), vertigo.<cite>Esc37</cite><cite>Esc38</cite>
|Dyspnoea (13.8%), haemorrhage, bruising; nausea (4.3%), vomiting, diarrhoea (3.7%), hypertension (3.8%), hypotension (3.2%), back pain (3.6%), abdominal pain, dyspepsia, gastritis, dizziness (4.5%), chest pain (3.7%), headache (6.5%), cough (4.9%), rash, pruritus, fatigue (3.2%),  constipation, arrhythmias including atrial fibrillation (4.2%), paraesthesia, confusion, hyperuricaemia, raised serum creatinine (7.4%), vertigo.<cite>Esc37</cite><cite>Esc38</cite>
|-
|-
!colspan="5"|Vitamin K Antagonists
|colspan="5" bgcolor="#E6E6FA"|'''Vitamin K Antagonists'''
|-
|-
|
|
Line 488: Line 486:
|valign="top"|Haemorrhage, nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency)
|valign="top"|Haemorrhage, nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency)
|-
|-
!colspan="5"|Lipid-Lowering Drugs
|colspan="5" bgcolor="#E6E6FA"|'''Lipid-Lowering Drugs'''
|-
|-
|rowspan="3"|Statins
|rowspan="3"|Statins
Line 506: Line 504:
|Hyperlipidaemias of types IIa, IIb, III, IV and V
|Hyperlipidaemias of types IIa, IIb, III, IV and V
|Gemfibrozil: 0.9-1.2mg daily
|Gemfibrozil: 0.9-1.2mg daily
|Gastro-intestinal
|Gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity<cite>Esc43</cite>
|-
|Ezetimibe
|Primary and familial hyper-cholesterolaemia
|10mg once daily
|Gastro-intestinal disturbance including diarrhoea (4.1%) and abdominal pain (3.0%); headache, fatigue (2.4%); myalgia, arthralgia (3.0%), sinusitis (3.6%), pharyngitis (2.3%), viral infection (2.2%), coughing (2.3%), hypersensitivity reactions including rash, angioedema, and anaphylaxis, hepatitis,pancreatitis, cholelithiasis, cholecystitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis<cite>Esc44</cite>
|}


==References==
==References==
467

edits

Navigation menu